75N93020F00006↗
Battelle Memorial Institute received this contract from National Institutes of Health Niaid, National Institutes of Health: $0 obligated so far for health r&d services; health care services; applied research. Its period of performance ended 2025-04-17.
Key facts · data as of Oct 28, 2026
- Recipient
- Battelle Memorial Institute
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Obligated to date
- $0
- Potential value
- $6.40M
- Ends
- 2025-04-17
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 28, 2026.
Cite this page: SpendQuery, Award 75N93020F00006, data as of Oct 28, 2026, https://spendquery.com/award?id=CONT_AWD_75N93020F00006_7529_75N93018D00013_7529
Battelle Memorial Institute: all federal awards · Department of Health and Human Services: spending · National Institutes of Health Niaid: what it buys
CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in Nanotechnology (NAICS 541713)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Competition
- Full and open competition
- Pricing
- Cost plus fixed fee
- How it was bought
- Single-award IDIQ · under 75N93018D00013
- Where the work is
- Franklin, OH · district OH-03
- Funding law
- COVID-19 laws
- Topics
- covid
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
4 subawards totaling $183.6K (18362365.0% of what was obligated), as Battelle Memorial Institute reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Integral Molecular Inc | $80.6K | 2 | PA | 2024-01-10 | 2024-11-17 |
| Danaher Corp | $62.5K | 1 | CA | 2023-12-14 | 2023-12-14 |
| Leinco Technologies, Inc. | $40.5K | 1 | MO | 2024-06-18 | 2024-06-18 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2023-12-14 | Beckman Coulter, Inc. | $62.5K | EQUIPMENT MAINTENANCE |
| 2024-11-17 | Integral Molecular Inc | $40.7K | SARS (COV 2) |
| 2024-06-18 | Leinco Technologies, Inc. | $40.5K | ANTI-SARS-COV-1 RECOMBINANT |
| 2024-01-10 | Integral Molecular Inc | $39.9K | LUCIFERASE REPORTERS |
Every action
7 actions since 2022-11-23. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-04-18 | P00012 | Terminated for convenience | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI FULL TERMINATION |
| 2024-01-25 | P00011 | Administrative change | $0 | CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
| 2023-10-11 | P00010 | Supplemental agreement (work within scope) | $0 | CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
| 2023-08-29 | P00009 | Supplemental agreement (work within scope) | $0 | CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
| 2023-07-10 | P00008 | Supplemental agreement (work within scope) | $0 | CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
| 2023-04-04 | P00007 | Supplemental agreement (work within scope) | $0 | CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
| 2022-11-23 | P00006 | Supplemental agreement (work within scope) | $0 | CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-28). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗